Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053885 · ClinicalTrials.gov registry record · Phase 2
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00053885 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 47 participants.
The verdict
NCT00053885, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
RATIONALE: PTK787/ZK 222584 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of PTK787/ZK 222584 in treating patients with unresectable malignant mesothelioma.
Interventions
- DRUG PTK787/ZK 222584
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2003-07 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053885
The ClinicalTrials.gov registry entry for NCT00053885 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTK787/ZK 222584 is the first listed.
NCT00053885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053885 about?
NCT00053885 is a clinical study titled "PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma". RATIONALE: PTK787/ZK 222584 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of PTK787/ZK 222584 in treating patients with unresectable malignant mesothelioma.
What is the current status of trial NCT00053885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2003-07. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00053885?
The interventions under investigation include: PTK787/ZK 222584 (DRUG).
Who is sponsoring clinical trial NCT00053885?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.